Advisors Preferred, LLC Abb Vie Inc. Transaction History

Advisors Preferred, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 30, 2024	BUY	$154.79 - $180.76 $314,378 - $367,123	2,031 New	2,031 $348,000
Q2 2023 Aug 04, 2023	BUY	$132.51 - $164.9 $86,661 - $107,844	654 Added 21.76%	3,660 $493,000
Q1 2023 May 03, 2023	SELL	$144.61 - $166.54 $97,177 - $111,914	-672 Reduced 18.27%	3,006 $479,000
Q4 2022 Feb 08, 2023	SELL	$138.31 - $165.87 $33,194 - $39,808	-240 Reduced 6.13%	3,678 $594,000
Q3 2022 Nov 07, 2022	SELL	$134.21 - $153.93 $69,654 - $79,889	-519 Reduced 11.7%	3,918 $541,000
Q2 2022 Aug 11, 2022	BUY	$137.62 - $174.96 $610,619 - $776,297	4,437 New	4,437 $680,000
Q2 2021 Jul 26, 2021	SELL	$105.21 - $117.21 $993,392 - $1.11 Million	-9,442 Closed	0 $0
Q1 2021 May 07, 2021	BUY	$102.3 - $112.62 $965,916 - $1.06 Million	9,442 New	9,442 $1.03 Million
Q4 2019 Jan 21, 2020	SELL	$72.13 - $90.25 $15,580 - $19,494	-216 Closed	0 $0
Q3 2019 Nov 12, 2019	SELL	$62.98 - $75.72 $108,136 - $130,011	-1,717 Reduced 88.83%	216 $16,000
Q2 2019 Aug 06, 2019	BUY	$65.7 - $83.98 $126,998 - $162,333	1,933 New	1,933 $142,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Advisors Preferred, LLC, based on Form 13F filings with the SEC.

Stay updated on Advisors Preferred, LLC with notifications on news.